{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:09:49Z","timestamp":1791828589718,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40744-023-00536-2","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T16:03:05Z","timestamp":1677168185000},"page":"679-691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis"],"prefix":"10.1007","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct04169373","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-852X","authenticated-orcid":false,"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6520-5619","authenticated-orcid":false,"given":"Marina","family":"Magrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"\u00d6st\u00f6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Saffore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Ho","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Ganz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Stigler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"536_CR1","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","volume":"80","author":"V Navarro-Comp\u00e1n","year":"2021","unstructured":"Navarro-Comp\u00e1n V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis. 2021;80:1511\u201321.","journal-title":"Ann Rheum Dis"},{"key":"536_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000053","volume":"1","author":"X Baraliakos","year":"2015","unstructured":"Baraliakos X, Braun J. Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? RMD Open. 2015;1: e000053.","journal-title":"RMD Open"},{"key":"536_CR3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777\u201383.","journal-title":"Ann Rheum Dis"},{"key":"536_CR4","first-page":"S319","volume":"25","author":"A Deodhar","year":"2019","unstructured":"Deodhar A. Understanding axial spondyloarthritis: a primer for managed care. Am J Manang Care. 2019;25:S319\u201330.","journal-title":"Am J Manang Care"},{"key":"536_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1136\/annrheumdis-2019-216143","volume":"79","author":"GJ Macfarlane","year":"2020","unstructured":"Macfarlane GJ, Rotariu O, Jones GT, Pathan E, Dean LE. Determining factors related to poor quality of life in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS). Ann Rheum Dis. 2020;79:202\u20138.","journal-title":"Ann Rheum Dis"},{"key":"536_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/rheumatology\/keh549","volume":"44","author":"KL Haywood","year":"2005","unstructured":"Haywood KL, Garratt AM, Dawes PT. Patient-assessed health in ankylosing spondylitis: a structured review. Rheumatology (Oxford). 2005;44:577\u201386.","journal-title":"Rheumatology (Oxford)"},{"key":"536_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/03009742.2018.1481225","volume":"48","author":"S Krabbe","year":"2019","unstructured":"Krabbe S, Glintborg B, \u00d8stergaard M, Hetland ML. Extremely poor patient-reported outcomes are associated with lack of clinical response and decreased retention rate of tumour necrosis factor inhibitor treatment in patients with axial spondyloarthritis. Scand J Rheumatol. 2019;48:128\u201332.","journal-title":"Scand J Rheumatol"},{"key":"536_CR8","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978\u201391.","journal-title":"Ann Rheum Dis"},{"key":"536_CR9","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/acr.24025","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res. 2019;71:1285\u201399.","journal-title":"Arthritis Care Res"},{"key":"536_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296:ard-2022-223296","author":"S Ramiro","year":"2022","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2022. https:\/\/doi.org\/10.1136\/ard-2022-223296:ard-2022-223296.","journal-title":"Ann Rheum Dis"},{"key":"536_CR11","doi-asserted-by":"publisher","first-page":"iv79","DOI":"10.1093\/rheumatology\/keaa435","volume":"59","author":"GE Fragoulis","year":"2020","unstructured":"Fragoulis GE, Siebert S. Treatment strategies in axial spondyloarthritis: what, when and how? Rheumatology (Oxford). 2020;59:iv79\u201389.","journal-title":"Rheumatology (Oxford)"},{"key":"536_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000524","volume":"3","author":"V Navarro-Comp\u00e1n","year":"2017","unstructured":"Navarro-Comp\u00e1n V, Plasencia-Rodr\u00edguez C, de Miguel E, et al. Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review. RMD Open. 2017;3: e000524.","journal-title":"RMD Open"},{"key":"536_CR13","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1136\/ard.2007.073569","volume":"66","author":"F Conti","year":"2007","unstructured":"Conti F, Ceccarelli F, Marocchi E, et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis. 2007;66:1393\u20137.","journal-title":"Ann Rheum Dis"},{"key":"536_CR14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Poddubnyy D, Pacheco-Tena C, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol (Hoboken, NJ). 2019;71:599\u2013611.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"536_CR15","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","volume":"80","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021;80:1004\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"536_CR16","doi-asserted-by":"publisher","first-page":"e002253","DOI":"10.1136\/rmdopen-2022-002253","volume":"8","author":"V Navarro-Comp\u00e1n","year":"2022","unstructured":"Navarro-Comp\u00e1n V, Wei JC, Van den Bosch F, et al. Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial. RMD Open. 2022;8(2):e002253.","journal-title":"RMD Open."},{"key":"536_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222608:annrheumdis-2022-222608","author":"D van der Heijde","year":"2022","unstructured":"van der Heijde D, Baraliakos X, Sieper J, et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis. 2022. https:\/\/doi.org\/10.1136\/ard-2022-222608:annrheumdis-2022-222608.","journal-title":"Ann Rheum Dis"},{"key":"536_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361\u20138.","journal-title":"Arthritis Rheum"},{"key":"536_CR19","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3899\/jrheum.151244","volume":"43","author":"MJ Kviatkovsky","year":"2016","unstructured":"Kviatkovsky MJ, Ramiro S, Landew\u00e9 R, et al. The minimum clinically important improvement and patient-acceptable symptom state in the BASDAI and BASFI for patients with ankylosing spondylitis. J Rheumatol. 2016;43:1680\u20136.","journal-title":"J Rheumatol"},{"key":"536_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ejpain.2003.09.004","volume":"8","author":"F Salaffi","year":"2004","unstructured":"Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain (London, England). 2004;8:283\u201391.","journal-title":"Eur J Pain (London, England)"},{"issue":"Suppl 11","key":"536_CR21","doi-asserted-by":"publisher","first-page":"S263","DOI":"10.1002\/acr.20579","volume":"63","author":"S Hewlett","year":"2011","unstructured":"Hewlett S, Dures E, Almeida C. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). Arthritis Care Res. 2011;63(Suppl 11):S263\u201386.","journal-title":"Arthritis Care Res"},{"key":"536_CR22","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1136\/annrheumdis-2017-212076","volume":"77","author":"U Kiltz","year":"2018","unstructured":"Kiltz U, van der Heijde D, Boonen A, et al. Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. Ann Rheum Dis. 2018;77:1311\u20137.","journal-title":"Ann Rheum Dis"},{"key":"536_CR23","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/annrheumdis-2017-212819","volume":"77","author":"N Richard","year":"2018","unstructured":"Richard N, Haroon N, Tomlinson GA, et al. FRI0208\u2005Ankylosing spondylitis quality of life: defining minimal clinically important change. Ann Rheum Dis. 2018;77:645.","journal-title":"Ann Rheum Dis"},{"key":"536_CR24","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.3899\/jrheum.110392","volume":"38","author":"V Strand","year":"2011","unstructured":"Strand V, Boers M, Idzerda L, et al. It\u2019s good to feel better but it\u2019s better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. J Rheumatol. 2011;38:1720\u20137.","journal-title":"J Rheumatol"},{"key":"536_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s40744-019-0155-5","volume":"6","author":"W Tillett","year":"2019","unstructured":"Tillett W, Lin CY, Zbrozek A, Sprabery AT, Birt J. A threshold of meaning for work disability improvement in psoriatic arthritis measured by the work productivity and Activity Impairment Questionnaire. Rheumatol Therapy. 2019;6:379\u201391.","journal-title":"Rheumatol Therapy"},{"key":"536_CR26","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s41687-022-00508-0","volume":"6","author":"D Cella","year":"2022","unstructured":"Cella D, Lenderking WR, Chongpinitchai P, et al. Functional assessment of chronic illness therapy-fatigue is a reliable and valid measure in patients with active ankylosing spondylitis. J Patient-Rep Outcomes. 2022;6:100.","journal-title":"J Patient-Rep Outcomes"},{"key":"536_CR27","first-page":"434","volume":"91","author":"J Siwek","year":"2015","unstructured":"Siwek J, Newman DH. Introducing medicine by the numbers: a collaboration of The NNT group and AFP. Am Fam Physician. 2015;91:434\u20135.","journal-title":"Am Fam Physician"},{"key":"536_CR28","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet (London, England). 2019;394:2108\u201317.","journal-title":"Lancet (London, England)"},{"key":"536_CR29","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1136\/annrheumdis-2019-215427","volume":"78","author":"LM \u00d8rnbjerg","year":"2019","unstructured":"\u00d8rnbjerg LM, Brahe CH, Askling J, et al. Treatment response and drug retention rates in 24 195 biologic-na\u00efve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. Ann Rheum Dis. 2019;78:1536\u201344.","journal-title":"Ann Rheum Dis"},{"key":"536_CR30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40744-019-0148-4","volume":"6","author":"T Hunter","year":"2019","unstructured":"Hunter T, Schroeder K, Sandoval D, Deodhar A. Persistence, discontinuation, and switching patterns of newly initiated TNF inhibitor therapy in ankylosing spondylitis patients in the United States. Rheumatol Therapy. 2019;6:207\u201315.","journal-title":"Rheumatol Therapy"},{"key":"536_CR31","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/RHU.0000000000000589","volume":"23","author":"V Strand","year":"2017","unstructured":"Strand V, Singh JA. Patient burden of axial spondyloarthritis. JCR J Clin Rheumatol. 2017;23:383\u201391.","journal-title":"JCR J Clin Rheumatol."},{"key":"536_CR32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12891-020-03247-9","volume":"21","author":"T Nadin","year":"2020","unstructured":"Nadin T, Wallis D, Holroyd CR, et al. Amongst patients taking biologic therapies for axial spondyloarthritis, which factors are associated with work non-participation? BMC Musculoskelet Disord. 2020;21:209.","journal-title":"BMC Musculoskelet Disord"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00536-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-023-00536-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00536-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T18:08:56Z","timestamp":1682618936000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-023-00536-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["536"],"URL":"https:\/\/doi.org\/10.1007\/s40744-023-00536-2","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"assertion":[{"value":"7 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}